Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy plus Epaloritovorelimab + Toripalimab + Trifluridine-Tipiracil + Bevacizumab as third-line therapy for metastatic colorectal cancer
ChiCTR2500107958Phase 2Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epaloritovorelimab, toripalimab, trifluridine + tipiracil and bevacizumab in metastatic colon cancer (mCRC), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
epaloritovorelimabtoripalimabtrifluridine + tipiracilbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2500107958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107958.